5302392025-10-012025-12-315302392025-04-012025-12-315302392025-10-012025-12-31in-capmkt:OtherExpenses1Member5302392025-10-012025-12-31in-capmkt:OtherExpenses2Member5302392025-04-012025-12-31in-capmkt:OtherExpenses1Member5302392025-04-012025-12-31in-capmkt:OtherExpenses2Member5302392025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15302392025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15302392025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss15302392025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares530239SUVENNOTLISTEDINE495B01038SUVEN LIFE SCIENCES LIMITEDMain BoardEquity2025-04-012026-03-312026-01-292026-01-22INRLakhsQuarterlyThird quarterSingle segmentThe Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented2026-01-2911:30:002026-01-2912:40:00Not applicable2025-10-012025-12-31UnauditedConsolidated280870002774500055832000000626840000134580009989080001075050000-10192180000-10192180000000-10192180000000-1019218000-7513000-10267310002274740001-4.55-4.5500-4.55-4.551) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 29, 2026. The results for the quarter ended December 31, 2025 has been reviewed by our statutory auditors. <BR> 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued the <BR> 3) The consolidated financial results include the results of the Wholly Owned Subsidiary, Suven Neurosciences, Inc. <BR> 4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. <BR> 5) ESOP for the quarter ended December 31, 2025, the Company recognized an employee benefit expense (EBP) of Rs. 25.71 lakhs in accordance with Ind AS 102 Share-based Payment. The cumulative EBP recognized as of December 2025 amounts to Rs.79.44 lakhs. <BR> During the II quarter, out of 2,21,800 options under the 1st tranche, 2,14,000 options were exercised, and the Company received Rs. 117.70 lakhs pursuant to the exercise of employee stock options under its ESOP scheme. As of the reporting date, the equity shares corresponding to these exercised options had been allotted on 24.07.2025. The remaining unexercised options under the 1st tranche continue to be available for exercise by eligible employees, as the vesting period extends until 06-May-2027. <BR> 6) Preferential Issue: The Board of Directors of the Company approved the issue of 6,40,02,999 convertible warrants on a preferential basis to 23 allottees in its meeting held on 13th May, 2025, in accordance with the provisions of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Subsequently, shareholders of the Company approved the issue of convertible warrants in their meeting held on 05th June, 2025. <BR> Each warrant is convertible into one equity share of face value Rs 1/- at an exercise price of Rs. 134/- per share, within a period of 18 months from the date of allotment. <BR> Out of the Issue proceeds of Rs.85,764 Lakhs, Rs.58,219 Lakhs has been received and Rs. 27,545 Lakhs is yet to be received from warrant holders. During the II quarter the Company has alloted 9186490 equity shares on a preferential basis upon conversion of equivalent number of fully paid warrants (allotted on 16.07.2025) to three allottees, upon receipt of 100% of the warrant consideration amounting to Rs.12,309.90 lakhs. <BR> Summary of Utilisation of Proceeds of Preferential issue as on 31.12.2025 <BR> Amout Received through Preferential Issue 58,218.72 <BR> Less: Amount Utilised 18,062.24 <BR> Balance Amount 40,156.48 <BR> 7) The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four Labour Code viz Code on wages 2019, Code on Social Security 2020, Industrial Relation Code 2020, and Occupational Safety, Health and Working Condition Code 2020 (collectively referred to as the New Labour Codes}. These Codes have been made effective from November 21, 2025. The corresponding supporting rules under these codes are yet to be notified. The Company is in the process of evaluating the full impact of these new labour codes. <BR> The Company has recognised and accounted for incremental liability for employee benefit expenses of Rs.36.34 Lakhs with respect to gratuity which is not material to the financial results. The Company continues to monitor the finalisation of Central/ State Rules and clarifications from the Government on other aspects of the New Labour Code. <BR> 8) The corresponding previous period figures have been regrouped / reclassified where ever necessary.2025-04-012025-12-31UnauditedConsolidated559460007152300012746900000018320500004031000022114400002434955000-23074860000-23074860000000-23074860000000-2307486000-7173000-23146590002274740001-10.31-10.3100-10.31-10.31R & D Expenses940472000Other Expenses58436000R & D Expenses2058569000Other Expenses152871000Items that will not be reclassified to profit or loss326000326000Items that will not be reclassified to profit or loss260002600000Items that will not be reclassified to profit or loss-7839000-7839000Items that will not be reclassified to profit or loss-7199000-719900000-7513000-7173000